TY - JOUR
T1 - Ecarin based coagulation testing
AU - Gosselin, Robert C
AU - Douxfils, Jonathan
N1 - © 2020 Wiley Periodicals LLC.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Ecarin is derived from venom of Echis carinatus, and will activate prothrombin into meizothrombin which will then cleave fibrinogen to result in clot formation. Ecarin based testing has been described for decades, but these assays were typically restricted to reference or speciality coagulation laboratories. This test was initially described for the assessment of direct thrombin inhibitors (eg, bivalirudin lepirudin, or argatroban) and was not affected by heparins or heparinoids. Ecarin based assays were rarely used for anticoagulation monitoring until the emergence of the direct oral thrombin inhibitor dabigatran etexilate in 2010. As this test was mentioned in the prescribing information for dabigatran etexilate, there was increased interest for use by clinical laboratories as the preferred method for assessing the anticoagulant effect of this drug. The purpose of this document is to review the current status of ecarin based assays for assessing dabigatran. This is with the understanding that these methods can also be exploited for determining the anticoagulation effect of parenteral direct thrombin inhibitors, such as argatroban and bivalirudin.
AB - Ecarin is derived from venom of Echis carinatus, and will activate prothrombin into meizothrombin which will then cleave fibrinogen to result in clot formation. Ecarin based testing has been described for decades, but these assays were typically restricted to reference or speciality coagulation laboratories. This test was initially described for the assessment of direct thrombin inhibitors (eg, bivalirudin lepirudin, or argatroban) and was not affected by heparins or heparinoids. Ecarin based assays were rarely used for anticoagulation monitoring until the emergence of the direct oral thrombin inhibitor dabigatran etexilate in 2010. As this test was mentioned in the prescribing information for dabigatran etexilate, there was increased interest for use by clinical laboratories as the preferred method for assessing the anticoagulant effect of this drug. The purpose of this document is to review the current status of ecarin based assays for assessing dabigatran. This is with the understanding that these methods can also be exploited for determining the anticoagulation effect of parenteral direct thrombin inhibitors, such as argatroban and bivalirudin.
KW - Antithrombins/pharmacokinetics
KW - Blood Coagulation Tests
KW - Dabigatran/pharmacokinetics
KW - Drug Monitoring
KW - Endopeptidases/chemistry
KW - Humans
UR - https://researchportal.unamur.be/en/publications/ecarin-based-coagulation-testing(7970ac07-58bb-4e79-9402-a134e05d9ec9).html
UR - http://www.scopus.com/inward/record.url?scp=85084516066&partnerID=8YFLogxK
U2 - 10.1002/ajh.25852
DO - 10.1002/ajh.25852
M3 - Review article
C2 - 32350907
SN - 2053-6631
VL - 95
SP - 863
EP - 869
JO - European Medical Journal Hematology
JF - European Medical Journal Hematology
IS - 7
ER -